cabotegravir

ViiV Healthcare reports data from Phase I trial of HIV drug
Clinical Trials Arena
Tue, 03/5/24 - 11:17 am
ViiV Healthcare
HUV
cabotegravir
clinical trials
GSK’s “crown jewels” already look tarnished
EP Vantage
Wed, 11/23/22 - 07:27 am
GSK
Blenrep
Emma Walmsley
daprodustat
gepotidacin
otilimab
Jemperli
Zejula
cabotegravir
GSK's ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms
Fierce Pharma
Tue, 11/30/21 - 11:24 pm
ViiV Healthcare
GSK
HIV
PrEP
cabotegravir
ViiV begins rolling submission for cabotegravir to prevent HIV in US
Pharmaceutical Business Review
Wed, 05/5/21 - 10:31 am
ViiV Healthcare
cabotegravir
HIV
FDA
GSK and ViiV score breakthrough therapy designation in HIV prevention, as Truvada showdown draws nearer
Endpoints
Tue, 11/17/20 - 11:12 pm
GSK
ViiV
FDA
cabotegravir
HIV
PrEP
GSK reports its long-acting HIV PrEP tops Gilead's Truvada — again
Endpoints
Mon, 11/9/20 - 11:56 am
GSK
ViiV
cabotegravir
HIV
PrEP
FDA
GSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada
Endpoints
Wed, 07/8/20 - 10:38 am
GSK
Gilead Sciences
ViiV Healthcare
HIV
cabotegravir
Truvada
GSK sub’s injectable outperforms Gilead in late-stage PrEP trial
Endpoints
Tue, 05/19/20 - 10:33 am
GSK
Gilead Sciences
HIV
PrEP
Truvada
ViiV Healthcare
cabotegravir
More threat to Gilead's HIV business? GlaxoSmithKline touts long-acting injectable PrEP win against Truvada
Fierce Pharma
Mon, 05/18/20 - 11:12 am
GSK
Gilead Sciences
Truvada
cabotegravir
HIV
PrEP
FDA slams GSK's monthly HIV injectable with CRL, citing manufacturing issues
Endpoints
Mon, 12/23/19 - 11:44 pm
FDA
complete response letter
GSK
HIV
cabotegravir
rilpivirine
GSK's ViiV reports positive data for long-acting two-drug HIV therapy
Biopharma Dive
Thu, 08/22/19 - 11:46 am
ViiV Healthcare
GSK
HIV
cabotegravir
rilpivirine
ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment
Pharmaceutical Business Review
Tue, 07/9/19 - 08:51 am
ViiV Healthcare
HIV
cabotegravir
rilpivirine
ViiV Submits NDA for Once-Per-Month HIV Injectable
BioSpace
Mon, 04/29/19 - 08:54 pm
ViiV Healthcare
FDA
HIV
HIV-1
cabotegravir
rilpivirine
Monthly shots control HIV as well as daily pills in two big studies
Stat
Thu, 03/7/19 - 09:21 pm
HIV
AIDS
JNJ
Janssen
ViiV Healthcare
cabotegravir
Edurant
Long-lasting HIV injection is a step closer after second GSK study
Reuters
Wed, 10/31/18 - 09:53 am
vaccines
GSK
HIV
cabotegravir
rilpivirine
Should Gilead Be Worried About This New Monthly HIV Medication?
Motley Fool
Thu, 08/16/18 - 10:09 am
Gilead Sciences
HIV
JNJ
ViiV
cabotegravir
rilpivirine
Edurant
Long-acting injection boosts hopes for GSK's HIV business
Yahoo/Reuters
Wed, 08/15/18 - 09:40 am
GSK
HIV
AIDS
cabotegravir
rilpivirine
ViiV
Fresh off its Juluca approval, GlaxoSmithKline beefs up trials of long-acting HIV duo
Fierce Pharma
Tue, 11/28/17 - 09:05 pm
GSK
cabotegravir
HIV
Endurant
ViiV
JNJ
Janssen
Johnson & Johnson HIV combination succeeds in mid-stage study
Yahoo/Reuters
Tue, 11/3/15 - 09:20 am
JNJ
HIV
cabotegravir
rilpivirine
ViiV Healthcare